Accéder au contenu
Merck

Somatic deletion of KDM1A/LSD1 gene is associated to advanced colorectal cancer stages.

Journal of clinical pathology (2019-09-01)
Ruth Ramírez-Ramírez, Melva Gutiérrez-Angulo, Jorge Peregrina-Sandoval, José Miguel Moreno-Ortiz, Ramon Antonio Franco-Topete, Felipe de Jesús Cerda-Camacho, Maria de la Luz Ayala-Madrigal
RÉSUMÉ

KDM1A/LSD1 and ZNF217 are involved in a protein complex that participates in transcriptional regulation. ZNF217 has been analysed in numerous cancers and its amplification has been associated with advanced stages of disease; however, a similar role for KDM1A/LSD1 has not been uncovered. In this study, we estimated the number of KDM1A/LSD1 and ZNF217 gene copies in tissue samples from patients diagnosed with colorectal cancer (CRC), as well as its association with clinicopathological features in patients with CRC. Paraffin-embedded tumour samples from 50 patients with CRC with a histopathological diagnosis of CRC were included. The number of copies of KDM1A/LSD1 and ZNF217 genes was determined by fluorescence in situ hybridisation (FISH). We also analysed the association between copy numbers of selected genes and clinicopathological data based on multivariate analysis. Deletion of the KDM1A/LSD1 gene occurred in 19 samples (38%), whereas ZNF217 gene amplification was identified in 11 samples (22%). We found a significant association between lymph node metastasis or advanced tumour stage and KDM1A/LSD1 gene deletion (p value=0.0003 and p value=0.011, respectively). KDM1A/LSD1 gene deletion could be considered a novel prognostic biomarker of late-stage CRC.